Your browser doesn't support javascript.
loading
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy.
Deng, Jing; Paulus, Aneel; Fang, Douglas D; Manna, Alak; Wang, Guangfeng; Wang, Hengbang; Zhu, Saijie; Chen, Jianyong; Min, Ping; Yin, Yan; Dutta, Navnita; Halder, Nabanita; Ciccio, Gina; Copland, John A; Miller, James; Han, Bing; Bai, Longchuan; Liu, Liu; Wang, Mi; McEachern, Donna; Przybranowski, Sally; Yang, Chao-Yie; Stuckey, Jeanne A; Wu, Depei; Li, Caixia; Ryan, Jeremy; Letai, Anthony; Ailawadhi, Sikander; Yang, Dajun; Wang, Shaomeng; Chanan-Khan, Asher; Zhai, Yifan.
Affiliation
  • Deng J; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Paulus A; Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida.
  • Fang DD; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, Florida.
  • Manna A; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Wang G; Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida.
  • Wang H; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Zhu S; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Chen J; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Min P; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Yin Y; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Dutta N; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Halder N; Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida.
  • Ciccio G; Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida.
  • Copland JA; Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida.
  • Miller J; Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida.
  • Han B; Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida.
  • Bai L; Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida.
  • Liu L; Department of Internal Medicine, Pharmacology and Medicinal Chemistry, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
  • Wang M; Department of Internal Medicine, Pharmacology and Medicinal Chemistry, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
  • McEachern D; Department of Internal Medicine, Pharmacology and Medicinal Chemistry, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
  • Przybranowski S; Department of Internal Medicine, Pharmacology and Medicinal Chemistry, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
  • Yang CY; Department of Internal Medicine, Pharmacology and Medicinal Chemistry, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
  • Stuckey JA; Department of Internal Medicine, Pharmacology and Medicinal Chemistry, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
  • Wu D; Department of Internal Medicine, Pharmacology and Medicinal Chemistry, Rogel Cancer Center, University of Michigan, Ann Arbor, Michigan.
  • Li C; Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
  • Ryan J; Department of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
  • Letai A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Ailawadhi S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Yang D; Department of Cancer Biology, Mayo Clinic, Jacksonville, Florida.
  • Wang S; Ascentage Pharma (Suzhou) Co., Ltd., Suzhou, Jiangsu, China.
  • Chanan-Khan A; Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
  • Zhai Y; Ascentage Pharma Group, Rockville, Maryland.
Clin Cancer Res ; 28(24): 5455-5468, 2022 12 15.
Article in En | MEDLINE | ID: mdl-36048524
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematologic Neoplasms / Proto-Oncogene Proteins c-bcl-2 / Antineoplastic Agents Type of study: Prognostic_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2022 Type: Article Affiliation country: China
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hematologic Neoplasms / Proto-Oncogene Proteins c-bcl-2 / Antineoplastic Agents Type of study: Prognostic_studies Limits: Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2022 Type: Article Affiliation country: China